The head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev on the air of the Russia 1 TV channel said about the rush demand for the Russian vaccine against the Sputnik V coronavirus around the world. Mr. Dmitriev associates this with the high efficacy and safety of the drug.
“We see a really absolutely rush demand for the Russian vaccine all over the world, and this is due to the fact that it shows the best results both in terms of efficiency and safety,” said Mr. Dmitriev.
He added that the effectiveness of the drug is confirmed not only by Russian studies, but also by data from Mexico, Argentina, Hungary and many other countries that use the Russian vaccine.
Sputnik V is currently approved in 66 countries with a total population of over 3.2 billion people. The effectiveness of the drug is 97.6%. On March 4, the relevant European regulator (EMA) announced the start of the procedure for the sequential examination of the vaccine.
Four vaccines against COVID-19 have been registered in Russia: Sputnik V, the first registered in the world, and its one-component version, Sputnik Light, from the Gamaleya Center, EpiVacCorona of the Vector Center and KoviVak of the Chumakov Center. In Russia, at least 11 million people were vaccinated with at least the first component of the vaccine.
When the Russian vaccine will be approved in European countries – in the material of Kommersant FM.